Cinacalcet Improves Control of Secondary Hyperparathyroidism in Peritoneal Dialysis: A Multicenter Study

Pórtoles, José; López–Sánchez, Paula; Bajo, María Auxiliadora; Castellano, Inés; Peso, Gloria del; Rodríguez, José Ramón; Ribera, Mayte; Ortigosa, Almudena; Selgas, Rafael

doi:10.3747/pdi.2011.00017

Cited by 4 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are no significant differences in the mechanism of onset and pathological state of SHPT between patients receiving HD and PD. Therefore, these patients receive similar treatments, including cinacalcet hydrochloride (cinacalcet), active vitamin D, and phosphate binders [4]. Because of the nature of PD, oral treatments are the preferred route of administration instead of intravenous injection.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients

et al. 2019

View full text Add to dashboard Cite

Background Secondary hyperparathyroidism (SHPT) is a serious and common complication in patients receiving peritoneal dialysis (PD). Cinacalcet is currently the recommended therapy for SHPT; however, gastrointestinal (GI)-related symptoms can result in low adherence and high discontinuation rates. Evocalcet is a novel calcimimetic agent that has non-inferior efficacy while providing a more tolerable safety profile. Methods This was a multicenter, intra-subject dose-adjustment treatment study evaluating the efficacy and safety of 1–8 mg evocalcet orally administered once daily for 32 weeks for the treatment of SHPT in PD patients. Patients then entered a 20-week extension period (dose range 1–12 mg). The primary endpoint was the proportion of patients who achieved a mean intact parathyroid hormone (iPTH) level of 60–240 pg/mL during the evaluation period (weeks 30–32). Secondary efficacy endpoints included the proportion of patients achieving ≥ 30% decrease in iPTH levels. Results A total of 39 Japanese PD patients with SHPT received evocalcet. The target mean iPTH level of 60–240 pg/mL was achieved by 71.8% (28/39) of patients during the evaluation period and 83.3% (20/24) of patients at week 52. The proportion of patients who achieved ≥ 30% decrease in iPTH levels from baseline was 74.4% (29/39) during the evaluation period and 87.5% (21/24) at week 52. Adverse drug reactions occurred in 46.2% (18/39) of patients, with most being of mild-to-moderate severity including GI-related events. Conclusion This study shows the long-term efficacy and safety of evocalcet when orally administered to PD patients with SHPT once daily. Clinical trial registration ClinicalTrials.gov: NCT02549417, https://clinicaltrials.gov/ct2/show/NCT02549417 ; JAPIC: JapicCTI-153016, http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-153016 . Electronic supplementary material The online version of this article (10.1007/s10157-019-01692-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Continuous presence of intra-abdominal fluid with adequate levels of calcium improve this imbalance and protect patients from hypocalcemia. Our major difference from the other studies of cinacalcet in PD patients 9,10 was the impossibility to improve the biochemical control of SHPT in PD patients after the second month of therapy. We prescribed cinacalcet in low doses (mean 45 mg/day) and only two patients tolerated doses of 90 mg/day.…”

Section: Discussionmentioning

confidence: 62%

“…In the first report, 9 discontinuation of cinacalcet administration was not required in any patient; in the second study, 10 all patients with digestive intolerance reduced or discontinued cinacalcet, with the appearance of side effects being similar or even lower than that reported for HD. 14 Additionally, in our report 92.6% of patients were treated with phosphate binders, which, alone, could lead to gastric intolerance.…”

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

Cinacalcet in peritoneal dialysis patients: one-center experience

Querido¹,

Branco²,

Sousa³

et al. 2017

Jornal Brasileiro De Nefrologia

View full text Add to dashboard Cite

“…However, increased use of vitamin D receptor agonists may be possible when the therapy is combined with cinacalcet (26,27). Cinacalcet is well tolerated and is shown to improve biochemical control of secondary hyperparathyroidism in PD patients (28).…”

Section: Discussionmentioning

confidence: 99%

Brown Tumor Management in End Stage Renal Disease Patients on Chronic Dialysis: Case Reports and Literature Review

Makusidi¹,

Yuvaraj²,

Mathew³

et al. 2014

Indian Journal of Peritoneal Dialysis

View full text Add to dashboard Cite

Abstract:Patients with CKD are prone to developing secondary and tertiary hyperparathyroidism due to altered calcium and phosphorus metabolism. Brown tumor is an uncommon terminal stage of cystic osteitis fibrosa which is being increasingly reported in hyperparathyroidism secondary to renal failure, as a result of increased survival of these patients on dialysis. We report four cases of brown tumors in end stage renal disease patients on maintenance dialysis at Madras Medical Mission Hospital who underwent parathyroidectomy with gratifying outcomes. Key words: Brown tumor, CKD, Dialysis, ParathyroidectomyIntroduction:

show abstract

Cinacalcet Improves Control of Secondary Hyperparathyroidism in Peritoneal Dialysis: A Multicenter Study

Abstract: main study limitations were the small size of the study cohort and the lack of a control group. CONCLUSIONSCinacalcet is well tolerated and may improve biochemical control of SHPT in PD patients.

Cited by 4 publications

References 9 publications

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients

Cinacalcet in peritoneal dialysis patients: one-center experience

Brown Tumor Management in End Stage Renal Disease Patients on Chronic Dialysis: Case Reports and Literature Review

Contact Info

Product

Resources

About